4.15
-0.72%
Close of 9 Nov 2026, in HKD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Sirnaomics
Its shares trade on HKEX under the ticker 2257.HK. It has been listed since 30 December 2021. In the fiscal year to 31 December 2024, it reported revenue of $1.8m and a net loss of $51.4m. At that date it held total assets of $28.3m and shareholders' equity of −$1.7m.
Sirnaomics Ltd. operates as a holding company. The company is headquartered in Gaithersburg, Maryland. The company went IPO on 2021-12-30. The firm and its subsidiaries are clinical-stage biotechnology companies that are engaged in developing and commercializing ribonucleic acid interference (RNAi) technology and multiple therapeutics. The firm is engaged in discovering and developing drugs for indications with unmet medical needs in areas. Its lead clinical drug candidates include STP705 and STP707. Its STP705 is a sterile drug product for the treatment of nonmelanoma skin cancer (NMSC), including squamous cell carcinoma in situ and basal cell carcinoma (BCC), recurrent keloids after keloidectomy, hypertrophic scar (HTS) and solid liver tumors, as well as for medical aesthetics. Its STP707 is a sterile drug product for the treatment of solid tumors, including liver cancer, metastatic cutaneous squamous-cell skin cancer (cSCC) and non-small cell lung cancer. The company is capitalizing on its dual delivery platforms, which include Polypeptide nanoparticle (PNP) and GalAhead.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 30 Dec 2021
- Employees
- 180
- Website
- sirnaomics.com ↗
Leadership
Pay as last reported
- Ms. Monin UngNon-Executive Independent Chairman of the Board$69,000
- Dr. Hung Fai PoonChief Executive Officer, Executive Director, since 2024
- Dr. David EvansExecutive Director, Head of Drug Discovery and Collaboration$469,000
- Dr. Yongxiang WangExecutive Director, Chief Production Officer, since 2020
- Mr. Yun Ting YuenCompany Secretary
- Mr. Jiankang ZhangNon-Executive Director$15,000
- Dr. Hoi Yu CheungNon-Executive Independent Director$46,000
- Mr. Yu Shan WongIndependent Non-Executive Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Sirnaomics Ltd. has 180 employees focused on RNAi technology development.
- STP705 and STP707 are clinical-stage drug candidates for unmet medical needs.
- Dual delivery platforms Polypeptide nanoparticle and GalAhead support therapeutic development.
Weaknesses
- Sirnaomics Ltd. is a clinical-stage biotechnology company with no commercial products yet.
- The company's lead drug candidates STP705 and STP707 are still in clinical stages.
- Sirnaomics Ltd. has no revenue from commercialized products as of 2021.
Opportunities
- STP705 targets nonmelanoma skin cancer and solid liver tumors with high unmet need.
- STP707 addresses solid tumors including liver cancer and metastatic cutaneous squamous-cell skin cancer.
- RNAi technology has potential for multiple therapeutic applications in Health Care sector.
Threats
- Clinical-stage biotechnology companies face high development risks for RNAi therapeutics.
- Competition in RNAi technology may emerge from other biotech firms.
- Regulatory approval delays could impact STP705 and STP707 development timelines.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.